Related Experiment Videos
Differential expression of the neuroendocrine polypeptide 7B2 in hypothalami of Prader-(Labhart)-Willi syndrome
B A Gabreëls1, D F Swaab, N G Seidah
1Graduate School of Neurosciences/Netherlands Institute for Brain Research, Amsterdam-Zuidoost.
Insights
Prader-Willi syndrome (PWS) involves genetic defects affecting chromosome 15. This study found altered expression of 7B2 gene products in most PWS patients, suggesting neuroendocrine dysfunction.
Area of Science:
- Neuroendocrinology
- Genetics
- Molecular Biology
Background:
- Prader-Willi syndrome (PWS) is a complex genetic disorder characterized by hypotonia, obesity, and developmental delays.
- PWS is often linked to deletions on chromosome 15q11-q13 or maternal uniparental disomy of chromosome 15.
- The 7B2 gene, located near the PWS critical region, is expressed in neuroendocrine cells, making it a candidate for PWS-related dysfunction.
Observation:
- This study investigated 7B2 gene product presence in the hypothalamus of five PWS patients.
- Five antibodies targeting different parts of the 7B2 precursor polypeptide were used.
- Three out of five PWS patients showed no reaction to the MON-102 antibody, unlike all 30 controls.
Findings:
- While not all PWS patients completely lacked 7B2 products, a significant modification in 7B2 expression was observed in most.
- One patient lacking MON-102 reactivity still showed positive results with other 7B2 antibodies.
- The findings indicate that complete absence of 7B2 is not essential for PWS, but its expression is altered.
Implications:
- Altered 7B2 expression in PWS patients suggests a role in neuroendocrine system dysfunction.
- The variable genetic background of PWS may explain the differing 7B2 expression patterns.
- Further research into 7B2's role could elucidate PWS pathogenesis and inform therapeutic strategies.
Abstract:
Prader-(Labhart-)Willi syndrome (PWS) is characterized by infantile hypotonia, early childhood obesity, mental deficiency, short stature, small hands and feet and hypogonadism. In 70% of the cases this syndrome is associated with a defect of chromosome 15 at 15q11-q13, close to the location of the 7B2 gene (15q13-q14). The majority of the remaining PWS patients display maternal uniparental disomy on chromosome 15. Since the 7B2 gene products are expressed in neuroendocrine cells that are probably affected in PWS, e.g. by a pleiotrophic influence of the neighboring deletion, the presence of 7B2 was studied in the supraoptic and paraventricular nucleus of the hypothalamus of five subjects clinically diagnosed as PWS patients using five antibodies against various parts of the 7B2 precursor polypeptide. Three of the five PWS patients studied showed no reaction to the 7B2 antibody MON-102, whereas all 30 control patients did. However, one of the three MON-102 non-reacting PWS patients reacted to other 7B2 antibodies. In conclusion, the vanishing of 7B2 gene products is not obligatory for PWS, possibly due to the variable genetic background of PWS patients. However, in most patients there is a clear modification of 7B2 expression, pointing to altered neuroendocrine functions.